End-of-day quote
Shenzhen S.E.
06:00:00 2024-04-18 pm EDT
5-day change
1st Jan Change
22.1
CNY
-0.45%
-7.72%
-26.75%
Guangzhou Wondfo Biotech Co.,Ltd : annual earnings release
March 26, 2020 at 10:15 am EDT
The company will report its earnings for FY 2019 on 03/31/2020. Generally, the company reports earnings better than estimates. In recent months, the 4 analysts from Standard & Poor's consensus have revised their EPS estimates downward.
© MarketScreener.com - 2020
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-25
CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-15
CI
Tranche Update on Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback Plan announced on July 5, 2023.
23-07-12
CI
Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback announced on July 5, 2023 has closed with 1,121,900 shares, representing 0.25% for CNY 30.1 million.
23-07-10
CI
Guangzhou Wondfo Biotech Co.,Ltd announces an Equity Buyback for CNY 50 million worth of its shares.
23-07-05
CI
Guangzhou Wondfo Biotech Co.,Ltd authorizes a Buyback Plan.
23-07-04
CI
Beijing PolySeq Technology Co., Ltd. announced that it has received CNY 100 million in funding from Guangzhou Wondfo Biotech Co.,Ltd, Guangzhou Sanmei Investment Management Center (Limited Partnership), Shangshi Capital, IDG Capital Partners Co., Ltd., Tsinghua Innovation Ventures
23-05-11
CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-25
CI
Guangzhou Wondfo Biotech Co.,Ltd Approves the Cash Dividend for the Year 2022, Payable on 18 May 2023
23-04-24
CI
Announcement on Resolutions of the 2022 Annual General Meeting of Guangzhou Wondfo Biotech
23-04-21
CI
Guangzhou Huiyin Tianyue Nominates Mr.Ge Xinhua as Supervisor
23-04-10
CI
Guangzhou Wondfo Biotech Co.,Ltd Proposes Final Cash Dividend for the Year 2022
23-03-31
CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-30
CI
Beijing PolySeq Technology Co., Ltd. announced that it expects to receive CNY 40 million in funding from Guangzhou Wondfo Biotech Co.,Ltd, Guangzhou Sanmei Investment Management Center (Limited Partnership), Shangshi Capital, IDG Capital Partners Co., Ltd., Tsinghua Innovation Ventures
23-03-19
CI
Investors bet on greed and fear as China loosens COVID grip
22-12-09
RE
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-27
CI
Tranche Update on Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback Plan announced on September 26, 2022.
22-10-12
CI
Guangzhou Wondfo Biotech Co.,Ltd's Equity Buyback announced on September 26, 2022, has expired with 1,046,200 shares, representing 0.24% for CNY 30.10 million.
22-10-10
CI
Guangzhou Wondfo Biotech Co.,Ltd announces an Equity Buyback for CNY 50 million worth of its shares.
22-09-26
CI
Guangzhou Wondfo Biotech Co.,Ltd authorizes a Buyback Plan.
22-09-25
CI
Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-25
CI
Guangzhou Wondfo Biotech Co.,Ltd announced that it expects to receive CNY 1 billion in funding
22-08-18
CI
Guangzhou Wondfo Biotech Co.,Ltd Announces Cash Dividend, Payable on 14 June 2022
22-06-08
CI
Guangzhou Wondfo Biotech Co.,Ltd Approves Cash Dividend for the Year 2021
22-05-23
CI
Guangzhou Wondfo Biotech Co.,Ltd. Announces Profit Distribution Proposal for 2021
22-04-25
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
GUANGZHOU WONDFO BIOTECH CO., LTD. is a China-based company principally engaged in research, manufacture and sales of point-of-care testing (POCT) reagents, POCT instrument and related products. According to the testing result, the Company' products can be divided into qualitative testing products and quantitative testing products. According to the usage, the Company' products include pregnancy testing series, infectious diseases testing series, drugs (drug abuse) testing series and chronic disease testing series. The Company's products are used in POCT, clinical test, field test and personal health management, among others.
More about the company
Last Close Price
22.1
CNY
Average target price
33.14
CNY
Spread / Average Target
+49.93%
Consensus
1st Jan change
Capi.
-26.75% 1.44B -1.04% 12.47B -17.29% 6.99B -2.21% 5.1B +2.77% 4.27B -4.79% 4.27B -49.94% 3.45B +7.65% 2.61B -15.92% 2.08B -3.66% 1.67B
Diagnostic & Testing Substances
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1